newsfilter
← Earnings
Earnings Releases·

Evommune — Third Quarter 2026 Earnings Summary

  • Reported zero revenue for Q3 and nine months ended September 30, 2026, reversing prior period gains from the Maruho collaboration; net losses widened to $30.9 million for the quarter (vs. $12.5 million in 2025) and $84.8 million for the nine months (vs. $40.6 million in 2025) driven by increased R&D and G&A expenses.
  • Completed a $30 million private placement in November 2026 at $6.04 per share and secured worldwide rights to EVO570 from Hinova Pharmaceuticals for a $30 million upfront payment, bringing total cash, equivalents, and investments to $262.3 million as of September 30, 2026.
  • Discontinued EVO756 development in atopic dermatitis following a Phase 2b failure to meet primary endpoints, while advancing a robust 2027 pipeline including Phase 2b initiation for EVO301 in atopic dermatitis (mid-2027) and Phase 1 trials for EVO570 and EVO646 (Q1–H1 2027).
  • Management projects a cash runway extending into the second half of 2029 to deliver multiple clinical milestones, with CEO Luis Peña characterizing 2027 as a year of execution focused on clinical catalysts and the potential for EVO301 to become a foundational atopic dermatitis therapy.
Company
EVOMMUNE INC
Sector
Healthcare
Industry
Biotechnology